Scholarlink

<p>Corticotropin-releasing hormone (CRH, also referred to as CRF), together with its related peptides and receptors, forms a physiological system that operates virtually ubiquitously throughout the body, regulating a wide range of mental, behavioral, cardiovascular, metabolic, immune, and reproductive functions, enabling mammals to adapt under both basal and stressful conditions. Recently, Auchus et al. and Newfield et al. reported the first clinical studies on the use of crinecerfont, a novel small-molecule CRH antagonist, as an adjunctive therapy for classic congenital adrenal hyperplasia (CAH). The addition of crinecerfont expands the therapeutic options beyond standard treatment with hydrocortisone and/or fludrocortisone, enhancing both biochemical and clinical disease control. Importantly, crinecerfont holds promise as a means of reducing the adverse effects associated with chronic glucocorticoid therapy, which remain a major concern in CAH management. While these findings highlight the therapeutic potential of CRH antagonists in CAH, their broader clinical applications across other disorders remain largely unexplored.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Stress-related disorders and nonpeptidic CRH antagonists

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月9日

查看全文
  • Dimitrios Vlachakis,
  • George P Chrousos

摘要

Corticotropin-releasing hormone (CRH, also referred to as CRF), together with its related peptides and receptors, forms a physiological system that operates virtually ubiquitously throughout the body, regulating a wide range of mental, behavioral, cardiovascular, metabolic, immune, and reproductive functions, enabling mammals to adapt under both basal and stressful conditions. Recently, Auchus et al. and Newfield et al. reported the first clinical studies on the use of crinecerfont, a novel small-molecule CRH antagonist, as an adjunctive therapy for classic congenital adrenal hyperplasia (CAH). The addition of crinecerfont expands the therapeutic options beyond standard treatment with hydrocortisone and/or fludrocortisone, enhancing both biochemical and clinical disease control. Importantly, crinecerfont holds promise as a means of reducing the adverse effects associated with chronic glucocorticoid therapy, which remain a major concern in CAH management. While these findings highlight the therapeutic potential of CRH antagonists in CAH, their broader clinical applications across other disorders remain largely unexplored.